PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/20.500.11779/1928
Browse
2 results
Search Results
Article Citation - WoS: 1Citation - Scopus: 2Dataseton Maternal Attitudes About Child Maltreatment in Nine Countries Using a Q-Sort Methodology(Elsevier, 2020-06-01) Mels, Cindy; Alink, Lenneke; Branger, Marjolein; Carcamo, Rodrigo; Van Ginkel, Joost); Wang, Lamei; Yavuz Müren, Melis; Asanjarani, Faramarz; Soares, Isabel; Emmen, Rosanneke; Selcuk, Bilge; Hsiao, Celia; Woudstra, Mi-lan; Mesman, JudiAnalyses of the present data are reported in the article "Crossing Boundaries: A Pilot Study of Maternal Attitudes about Child Maltreatment in Nine Countries"[8]. Data were collected during home visits using the Maltreatment Q-Sort (MQS). A total of 466 mothers from nine different countries gave their opinion about child maltreatment by sorting 90 cards with parenting behaviors taken from the literature that reflect four types of child maltreatment, into 9 evenly distributed stacks (with 10 cards each) from least to most harmful for the child. This data article provides an overview of the content of the 90 items, which type of maltreatment they reflect, and the source of the items. The percentage of mothers labelling each of the MQS items as maltreatment is also presented. In addition, instructions are included about the administration of the MQS as well as data-entry and analyses of Q-sort data, accompanied by example datasets and syntaxes. This can serve as a manual for researchers interested in using Q-sort data.Article Citation - Scopus: 4Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey(Elsevier Inc., 2015-09-01) Altinbaş, Akif; Baser E; Kariburyo, F; Başer, Onur; Baser, Erdem; Kariburyo, M. FurahaBackground: According to the Turkish Ministry of Health’s guidelines,standard double therapy, a combination of pegylated interferon-alphaand ribavirin, was the only treatment option for patients withhepatitis C virus (HCV) infection until the end of 2011. Objective: Theprimary objective was to compare risk-adjusted clinical and economicoutcomes between treated and untreated patients with HCV infection.Methods: Patients with HCV infection were identified from theTurkish National Health Insurance Database (2009–2011) using International Classification of Diseases, 10th Revision, Clinical Modification codes.The first prescription date was designated as the index date. Mortalityand hepatocellular carcinoma (HCC) rates and health care costs oftreated and untreated patients were compared using propensity scorematching. Baseline demographic and clinical factors were controlledin the models. Subgroup analysis was conducted for patient groupswith and without a cirrhosis diagnosis. Results: Out of 12,990 patientsincluded in the study, 1,583 were treated for HCV infection. Out of2,467 patients who had a cirrhosis diagnosis, 231 were treated,whereas out of 10,523 patients without cirrhosis, 1,352 patients weretreated. Treated patients were younger, less likely to be diagnosedwith comorbid conditions, and less likely to reside in Central orEastern Anatolia. After adjusting for baseline demographic andclinical factors, mortality (2.27% vs. 5.31%; P o 0.001) and HCC rates(0.69% vs. 1.96%; P o 0.001) were found to be lower for treatedpatients. Differences were more significant among patients diagnosedwith cirrhosis. Treated patients incurred higher risk-adjusted annualcosts (€6172 vs. €1680; P o 0.001), mainly because of pharmaceuticalcosts (€4918 vs. €583; P o 0.001). Conclusions: HCV infection treatment, although costly, significantly reduces mortality and HCC ratesin Turkey.